Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Chemotherapy, Pembrolizumab and Radiation in Node(+), Triple Negative Breast Cancer
NCT07276880Phase 2Recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Mar 2026
- Primary completion
- Nov 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in triple-negative breast cancer (TNBC), sponsored by UNC Lineberger Comprehensive Cancer Center. Started Mar 2026; status: recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07276880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07276880.